UNSPSC 51291703: Clemeprol

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R3TC4SEW5A. European Medicines Agency schedules Clemeprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06649MIG. Clemeprol generally arises in the molecular formula C17H20CLNO. The term CLEMEPROL is an International Non-Proprietary Name or INN. CLEMEPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule clemeprol under HS 29221980 and SITC 51461. As of Q4 2014, CLEMEPROL remains the US FDA Preferred Term for this commodity. Clemeprol bears US NLM identifiers UMLS ID C0612052 and NCI Concept Code C79858. SMILES: Clc1ccc(C(C(O)CN(C)C)c2ccccc2)cc1.

UNSPSC 51291703 Clemeprol is a Commodity code covering pharmaceutical products — specifically naloxone, drug deactivation systems, and generic multi-source pharmaceuticals and over-the-counter products that state and local health agencies, community health departments, and cooperative purchasing alliances procure for public health, emergency response, and pharmacy benefit programs. State and local buyers under this code include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances that aggregate demand across participating jurisdictions. The work being solicited ranges from direct product procurement with specified unit quantities and delivery schedules to strategic sourcing initiatives that establish framework agreements with manufacturers through authorized wholesalers, with vendors typically responsible for logistics, regulatory compliance (cGMP, DSCSA, FDA requirements), and adherence to insurance and workplace certification standards.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program that would establish direct contracting channels between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, evaluation weighted 75 percent on price competitiveness, and contract effectiveness on July 1, 2026.